Evotec CSO: BMS Opt In On CNS Compound ‘Augurs Well’ For Discovery Pact

Further promising compounds will be explored after Bristol Myers Squibb exercised its option to enter an exclusive license for Evotec’s investigational EVT8683, generated by the German group’s iPSC platform as a potential treatment for neurodegenerative conditions.